Article
Oncology
ChuanLiang Cui, Xuan Wang, Bin Lian, Qing Ji, Li Zhou, Zhihong Chi, Lu Si, Xinan Sheng, Yan Kong, Jiayi Yu, Siming Li, Lili Mao, Bixia Tang, Jie Dai, Xieqiao Yan, Xue Bai, Robert Andtbacka, Jun Guo
Summary: The modified oncolytic virus OrienX010 was evaluated in Chinese patients with melanoma, and the results showed that it had antitumor effects in both injected and non-injected lesions with tolerable safety profile. The higher dose was selected as the recommended dose for ongoing trials based on these findings.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Galabina Bozhanova, Jehanne Hassan, Lizzie Appleton, Victoria Jennings, Shane Foo, Martin McLaughlin, Charleen M. L. Chan Wah Hak, Emmanuel C. Patin, Eva Crespo-Rodriguez, Gabby Baker, Edward Armstrong, Matthew Chiu, Hardev Pandha, Adel Samson, Victoria Roulstone, Joan Kyula, Richard Vile, Fiona Errington-Mais, Malin Pedersen, Kevin Harrington, Masahiro Ono, Alan Melcher
Summary: Combination therapy of HSV and BRAFi shows potential immunogenicity for BRAF mutant melanoma, but cannot fully control tumor growth. Changes in T cell dynamics within tumors, with relatively maintained antigen signaling in Treg compared with CD4+ effector cells, indicate a therapeutic role for CD4+ effector cells in controlling tumor growth. Depletion of Treg by addition of an anti-CD25 immune checkpoint inhibitor enhances survival and activates immune signaling within tumors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Biology
Tedi Ramaj, Xingfu Zou
Summary: In this study, a mathematical model of oncolytic virotherapy for melanoma treatment is developed and analyzed. The model considers the impact of hypoxia on tumor dynamics and the engineering design of oncolytic viruses. The results show that oxygen-rich environments favor the use of adenoviruses as oncolytic agents and emphasize the importance of balancing viral infection and oncolytic capabilities in the engineering of these viruses.
MATHEMATICAL BIOSCIENCES
(2023)
Review
Neurosciences
Sauson Soldozy, Kathleen M. Mulligan, David X. Zheng, Melissa A. Levoska, Christopher R. Cullison, Turki Elarjani, Daniel G. Eichberg, Leonel E. Ampie, Ashish H. Shah, Kaan Yagmurlu, Mark E. Shaffrey, Jeffrey F. Scott, Ricardo J. Komotar
Summary: Current evidence for oncolytic virotherapy treatment of melanoma is mostly limited to T-VEC, with a lack of data specifically regarding brain tumor metastasis. Despite promising findings, further investigation is needed.
Review
Pharmacology & Pharmacy
Alberto Reale, Arianna Calistri, Jennifer Altomonte
Summary: Oncolytic viruses are a new class of therapeutic agents with multiple mechanisms of action, including direct cancer cell-killing, immunotherapy, and gene therapy. Developing an effective delivery system, such as using carrier cells, is crucial to accelerate the clinical advancement of oncolytic viruses. Mesenchymal stem cells have been heavily investigated as carrier cells due to their inherent tumor tropism.
Review
Biochemistry & Molecular Biology
Valentina Marchica, Federica Costa, Gaetano Donofrio, Nicola Giuliani
Summary: Multiple myeloma is a hematologic malignancy that depends on the microenvironment, and despite improvements in survival with new drugs, drug resistance and relapse remain issues, necessitating the development of new treatment strategies. Oncolytic virotherapy shows promise in cancer treatment, with various human viruses being studied in preclinical models and in clinical trials for MM patients, while the use of non-human viruses is also being explored to potentially avoid immune responses that could reduce efficacy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Tianyue Chen, Xiangqing Ding, Qibin Liao, Nan Gao, Ye Chen, Chen Zhao, Xiaoyan Zhang, Jianqing Xu
Summary: Through this study, IL-21 and TTV were identified as the most potent immunomodulatory molecule and oncolytic virus for solid tumor suppression in mouse models. A novel recombinant oncolytic virus resulting from their combination, namely rTTV Delta TK-mIL21, showed significant anti-tumor activity in mice.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Miriam Valenzuela-Cardenas, Cody Gowan, Parker Dryja, Mee Y. Bartee, Eric Bartee
Summary: This study generated a doubly recombinant oncolytic virus that expresses PD1 and IL-12 fusion protein to treat solid tumors. The results revealed that the inflammation induced by the virus during therapy has a dual effect, and blocking the TNF pathway can enhance the therapeutic efficacy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Mathematics, Applied
Konstantin E. Starkov, Anatoly N. Kanatnikov, Giovana Andres
Summary: Through studying a three-dimensional model for tumor growth, we found conditions under which the system converges to equilibrium points, resulting in global eradication of uninfected or infected tumor cells based on algebraic inequalities related to virus replication rate. Furthermore, we observed the phenomenon where local eradication of infected tumor cells implies their global eradication.
COMMUNICATIONS IN NONLINEAR SCIENCE AND NUMERICAL SIMULATION
(2021)
Article
Oncology
Tianyu Tang, Xing Huang, Gang Zhang, Tingbo Liang
Summary: Oncolytic peptides are highly effective in remodeling the tumor microenvironment and enhancing anticancer immunity by inducing immunogenic cell death. A recent study shows that LTX-315 inhibits PD-L1 expression via ATP11B, thereby enhancing the effectiveness of cancer immunotherapy by targeting the PD-1/PD-L1 axis. This commentary discusses the broad effects and perspectives of oncolytic peptides on anticancer immunity, as well as the potential issues and directions in cancer immunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Biotechnology & Applied Microbiology
Jinhu Ma, Chunxue Zhang, Gang Shi, Dan Yue, Yongheng Shu, Shichuan Hu, Zhongbing Qi, Yanwei Chen, Bin Zhang, Yong Zhang, Anliang Huang, Chao Su, Yan Zhang, Hongxin Deng, Ping Cheng
Summary: Combination therapy is a promising direction for oncolytic virotherapy, as monotherapies with oncolytic viruses (OVs) have limited efficacy. This study explored the synergistic antitumor effect of high-dose vitamin C (VitC) in combination with oncolytic adenoviruses (oAds). The combination therapy enhanced immunogenic tumor cell death, increased T cells in the tumor microenvironment, and reprogramed the immunosuppressive tumor microenvironment.
Review
Pharmacology & Pharmacy
Gelare Ghajar-Rahimi, Kyung-Don Kang, Stacie K. Totsch, Sam Gary, Abbey Rocco, Sarah Blitz, Kara Kachurak, M. R. Chambers, Rong Li, Elizabeth A. Beierle, Asim Bag, James M. Johnston, James M. Markert, Joshua D. Bernstock, Gregory K. Friedman
Summary: Malignant brain tumors are a significant health issue in children and current treatment options have poor outcomes and long-term morbidity. Oncolytic virotherapy has emerged as a promising immunotherapy for pediatric brain tumors. This review focuses on past and current clinical trials using oncolytic virotherapy in pediatric brain tumors and discusses future research directions.
PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Virology
Ifeanyi Kingsley Uche, Natalie Fowlkes, Luan Vu, Tatiane Watanabe, Mariano Carossino, Rafiq Nabi, Fabio del Piero, Jared S. Rudd, Konstantin G. Kousoulas, Paul J. F. Rider
Summary: Oncolytic virotherapy (OVT) uses viral infection to release tumor antigens, promoting antitumor immune responses. VC2, a modified herpes simplex virus, shows clinical potential in a mouse melanoma model and may be an effective treatment for human and animal cancers.
JOURNAL OF VIROLOGY
(2021)
Article
Oncology
Supaporn Numpadit, Chiaki Ito, Takaaki Nakaya, Katsuro Hagiwara
Summary: Malignant melanoma, a highly invasive and metastatic cancer, poses limited treatment options for advanced-stage and metastatic oral melanoma. Oncolytic viral therapy, particularly using a recombinant Newcastle disease virus (rNDV) that promotes IFN? release, shows promise as a treatment option. In this study, canine oral melanoma cells were used as a model to evaluate the tumor lytic effect of the virus. The results demonstrated varying infection rates and oncolytic effects depending on the melanoma cells, with greater effects observed for IFN?-expressing virus and induced expression of Th1 cytokines by lymphocytes co-cultured with the virus.
Review
Oncology
Raquela J. Thomas, Eric Bartee
Summary: Surgical removal of tumors is a front-line therapy for cancer, but often fails to eradicate the disease completely. To improve surgical outcomes, patients are often given non-curative treatments before surgery. Oncolytic virotherapy has been identified as potentially effective in the neoadjuvant setting.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Surgery
Kristy M. Broman, Tasha C. Hughes, Brooke Bredbeck, James Sun, Dennis J. Kirichenko, Michael Carr, Avinash Sharma, Edmund Bartlett, Amanda A. G. Nijhuis, John F. Thompson, Tina J. Hieken, Lisa Kottschade, Jennifer Downs, David E. Gyorki, Emma Stahlie, Alexander van Akkooi, David Ollila, Kristin O'shea, Yun Song, Giorgos Karakousis, Marc Moncrieff, Jenny Nobes, John Vetto, Dale Han, Meghan Hotz, Jeffrey M. Farma, Jeremiah L. Deneve, Martin D. Fleming, Matthew Perez, Kirsten Baecher, Michael Lowe, Roger Olofsson Bagge, Jan Mattsson, Ann Y. Lee, Russell S. Berman, Harvey Chai, Hidde M. Kroon, Juri Teras, Roland M. Teras, Norma E. Farrow, Georgia M. Beasley, Jane Yuet Ching Hui, Lukas Been, Schelto Kruijff, Brandy Sinco, Amod A. Sarnaik, Vernon K. Sondak, Jonathan S. Zager, Lesly A. Dossett
Summary: The aim of this study was to determine trends and variation in the utilization of CLND and adjuvant systemic therapy for SLN-positive melanoma. The study found a decline in CLND and an increase in adjuvant systemic therapy. There was significant variation among treating centers, and location of care contributed significantly to the observed variation.
Article
Oncology
Austin Eckhoff, Norma E. Farrow, Caitlin Silvestri, Emily Stroobant, Charles Intenzo, Margaret Leddy, Douglas S. Tyler, Adam Berger, Georgia M. Beasley
Summary: Use of TcTM in SLNB is associated with significantly shorter LS mapping time while identifying similar numbers of SLN, with similar FNR between the two agents.
JOURNAL OF SURGICAL ONCOLOGY
(2022)
Letter
Dermatology
Andrew D. Tieniber, Adrienne B. Shannon, Michael J. Carr, James Sun, Karenia Landa, Kirsten M. Baecher, Kevin Lynch, Harrison G. Bartels, Robyn Panchaud, Michael C. Lowe, Craig L. Slingluff, Mark J. Jameson, Kenneth Y. Tsai, Mark B. Faries, Georgia M. Beasley, Vernon K. Sondak, Giorgos C. Karakousis, Jonathan S. Zager, John T. Miura
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2023)
Article
Dermatology
Melissa M. Sarver, Jess D. Rames, Georgia M. Beasley, Junheng Gao, Suephy C. Chen
Summary: This study compared the tumor distributions and survival characteristics between patients with second primary melanomas and those with single primary melanomas. The findings demonstrated that patients with second primary melanomas had better survival probabilities and thinner lesions. The results support the importance of full body skin examinations, with attention to the region of initial diagnosis.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2023)
Article
Surgery
Kristen E. Rhodin, Elizabeth M. Gaughan, Vignesh Raman, April K. Salama, Brent A. Hanks, Riddhishkumar Shah, Douglas S. Tyler, Craig L. Slingluff Jr, Georgia M. Beasley
Summary: This study aimed to evaluate the feasibility and impact of neoadjuvant therapy (NT) in patients with advanced melanoma amenable to surgical resection. Prospective data from 3 institutions showed that NT could potentially be effective in patients with advanced melanoma eligible for surgery.
Article
Oncology
Kevin T. Lynch, Yinin Hu, Norma E. Farrow, Yun Song, Max O. Meneveau, Minyoung Kwak, Michael C. Lowe, Edmund K. Bartlett, Georgia M. Beasley, Giorgos C. Karakousis, Craig L. Slingluff
Summary: This study retrospectively reviewed patients who underwent PLND and found that PLND may provide adequate regional disease control with a lower morbidity rate compared to CLND.
JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Cimarron E. Sharon, Georgia M. Beasley, Giorgos C. Karakousis
Summary: The current guidelines for the surgical care of cutaneous melanoma have been shaped by multiple randomized controlled clinical trials. These trials have provided important guidance for margin excision and sentinel lymph node biopsy in melanoma patients, and the development of targeted therapy and immunotherapy has offered effective adjuvant treatment options.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
(2023)
Article
Oncology
Georgia M. Beasley, Michael C. Brown, Norma E. Farrow, Karenia Landa, Rami N. Al-Rohil, Maria Angelica Selim, Aaron D. Therien, Sin-Ho Jung, Junheng Gao, David Boczkowski, Eda K. Holl, April K. S. Salama, Darell D. Bigner, Matthias Gromeier, Smita K. Nair
Summary: In patients with melanoma, those who had intratumoral inflammation and immune cell infiltrates after anti-PD-1 therapy and lerapolturev treatment had a longer progression-free survival, and they also exhibited stronger immune responses in peripheral blood.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Letter
Oncology
Cimarron E. Sharon, Gabriella N. Tortorello, Phyllis A. Gimotty, Georgia M. Beasley, Craig L. Slingluff, John T. Miura, Giorgos C. Karakousis
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Michael C. Brown, Georgia M. Beasley, Zachary P. McKay, Yuanfan Yang, Annick Desjardins, Dina M. Randazzo, Daniel Landi, David M. Ashley, Darell D. Bigner, Smita K. Nair, Matthias Gromeier
Summary: This study reveals the contribution of pre-existing anti-polio immunity to the effectiveness of polio virotherapy for cancer treatment. Childhood vaccines such as polio and tetanus can enhance antitumor immune responses, particularly by activating CD4(+) T cells and eosinophils.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Editorial Material
Oncology
Kristen E. Rhodin, Georgia M. Beasley
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Kristen E. Rhodin, Sin-Ho Jung, Kelly Elleson, Danielle DePalo, Richard Straker, Sophia McKinley, Kate Beekman, Lily Parker, Suephy Chen, Matthew K. Iyer, April K. S. Salama, Edmund Bartlett, Giorgos Karakousis, Jonathan S. Zager, Douglas S. Tyler, Georgia M. Beasley
Summary: This study investigated the impact of the timing of adjuvant immune checkpoint inhibitor (ICI) initiation on survival in patients with stage III melanoma. The results showed that patients who initiated adjuvant ICI within 6 weeks of surgery had worse recurrence-free survival, while those who started treatment after 6 weeks had improved outcomes.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Immunology
Austin M. Eckhoff, Michael C. Brown, Karenia Landa, Ibtehaj Naqvi, Eda K. Holl, David Boczkowski, Ashley Fletcher, Kristen E. Rhodin, Minh Huy Giang, Bruce Sullenger, Georgia M. Beasley, Peter J. Allen, Smita K. Nair
Summary: This study found that monocytes in the periphery and tumor microenvironment of patients with intraductal papillary mucinous neoplasm (IPMN) and pancreatic adenocarcinoma (PDAC) undergo functional changes and are associated with immunosuppression and immune evasion. Furthermore, the study also revealed that TLR activation is positively correlated with disease progression from IPMN to PDAC. These findings suggest that innate immune reprogramming occurs as IPMNs progress to invasive disease, partly mediated by soluble mediators in sera.
FRONTIERS IN IMMUNOLOGY
(2023)
Meeting Abstract
Oncology
Kristen E. Rhodin, Danielle Bello, Norma Farrow, Paul Mosca, April K. Salama, Smita Nair, Douglas Tyler, Charlotte Ariyan, Georgia Beasley
ANNALS OF SURGICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Aaron D. Therien, Eda K. Holl, Rami Al-Rohil, Kristen E. Rhodin, Douglas Tyler, Smita Nair, Georgia Beasley
ANNALS OF SURGICAL ONCOLOGY
(2022)